Amgen Financial Statements (AMGN)
|
|
|
|
Report date
|
|
|
16.02.2022 |
09.02.2023 |
14.02.2024 |
14.02.2025 |
13.02.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
25 979 |
26 323 |
28 190 |
33 424 |
36 741 |
|
37 238 |
|
Operating Income, bln rub |
|
|
7 639 |
9 566 |
7 897 |
7 258 |
10 676 |
|
11 778 |
|
EBITDA, bln rub |
? |
|
11 296 |
12 169 |
14 801 |
13 356 |
15 843 |
|
17 345 |
|
Net profit, bln rub |
? |
|
5 893 |
6 552 |
6 717 |
4 090 |
7 711 |
|
7 800 |
|
|
OCF, bln rub |
? |
|
9 261 |
9 721 |
8 471 |
11 490 |
9 958 |
|
10 756 |
|
CAPEX, bln rub |
? |
|
880.0 |
936.0 |
1 112 |
1 096 |
1 858 |
|
2 159 |
|
FCF, bln rub |
? |
|
8 381 |
8 785 |
7 359 |
10 394 |
8 100 |
|
8 597 |
|
Dividend payout, bln rub
|
|
|
4 013 |
4 196 |
4 556 |
4 832 |
5 124 |
|
5 203 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
68.1% |
64.0% |
67.8% |
118.1% |
66.5% |
|
66.7% |
|
|
OPEX, bln rub |
|
|
11 886 |
10 351 |
11 842 |
13 308 |
15 336 |
|
14 833 |
|
Cost of production, bln rub |
|
|
6 454 |
6 406 |
8 415 |
12 858 |
10 729 |
|
10 627 |
|
R&D, bln rub |
|
|
6 324 |
4 434 |
4 784 |
5 964 |
6 974 |
|
7 514 |
|
Interest expenses, bln rub |
|
|
1 197 |
1 406 |
2 875 |
3 155 |
2 755 |
|
2 703 |
|
|
Assets, bln rub |
|
|
61 165 |
65 121 |
97 154 |
91 839 |
90 586 |
|
92 504 |
|
Net Assets, bln rub |
? |
|
6 700 |
3 661 |
6 232 |
5 877 |
8 658 |
|
9 190 |
|
Debt, bln rub |
|
|
33 309 |
38 945 |
64 613 |
60 099 |
54 604 |
|
57 323 |
|
Cash, bln rub |
|
|
8 037 |
9 305 |
10 944 |
11 973 |
9 129 |
|
12 038 |
|
Net debt, bln rub |
|
|
25 272 |
29 640 |
53 669 |
48 126 |
45 475 |
|
45 285 |
|
|
Ordinary share price, rub |
|
|
225.0 |
|
|
260.6 |
327.3 |
|
335.6 |
|
Number of ordinary shares, mln |
|
|
570.0 |
538.0 |
535.0 |
541.0 |
538.0 |
|
540.0 |
|
|
Market cap, bln rub |
|
|
128 233 |
0 |
0 |
141 006 |
176 093 |
|
181 219 |
|
EV, bln rub |
? |
|
153 505 |
29 640 |
53 669 |
189 132 |
221 568 |
|
226 504 |
|
Book value, bln rub |
|
|
-23 372 |
-27 948 |
-45 038 |
-40 459 |
-32 298 |
|
-30 863 |
|
|
EPS, rub |
? |
|
10.3 |
12.2 |
12.6 |
7.56 |
14.3 |
|
14.4 |
|
FCF/share, rub |
|
|
14.7 |
16.3 |
13.8 |
19.2 |
15.1 |
|
15.9 |
|
BV/share, rub |
|
|
-41.0 |
-51.9 |
-84.2 |
-74.8 |
-60.0 |
|
-57.2 |
|
|
EBITDA margin, % |
? |
|
43.5% |
46.2% |
52.5% |
40.0% |
43.1% |
|
46.6% |
|
Net margin, % |
? |
|
22.7% |
24.9% |
23.8% |
12.2% |
21.0% |
|
20.9% |
|
FCF yield, % |
? |
|
6.54% |
|
|
7.37% |
4.60% |
|
4.74% |
|
ROE, % |
? |
|
88.0% |
179.0% |
107.8% |
69.6% |
89.1% |
|
84.9% |
|
ROA, % |
? |
|
9.63% |
10.1% |
6.91% |
4.45% |
8.51% |
|
8.43% |
|
|
P/E |
? |
|
21.8 |
0.00 |
0.00 |
34.5 |
22.8 |
|
23.2 |
|
P/FCF |
|
|
15.3 |
0.00 |
0.00 |
13.6 |
21.7 |
|
21.1 |
|
P/S |
? |
|
4.94 |
0.00 |
0.00 |
4.22 |
4.79 |
|
4.87 |
|
P/BV |
? |
|
-5.49 |
0.00 |
0.00 |
-3.49 |
-5.45 |
|
-5.87 |
|
EV/EBITDA |
? |
|
13.6 |
2.44 |
3.63 |
14.2 |
14.0 |
|
13.1 |
|
Debt/EBITDA |
|
|
2.24 |
2.44 |
3.63 |
3.60 |
2.87 |
|
2.61 |
|
|
R&D/CAPEX, % |
|
|
718.6% |
473.7% |
430.2% |
544.2% |
375.3% |
|
348.0% |
|
|
CAPEX/Revenue, % |
|
|
3.39% |
3.56% |
3.94% |
3.28% |
5.06% |
|
5.80% |
|
| Amgen shareholders |
